In the latest Nature study, the ADT+enzalutamide+anti-PD-L1 triplet regimen provided a superior OS benefit and the most significant reduction in tumor volume in prostate cancer and sarcoma models compared to the duplex regimen, and it appears that ADT enhanced the synergistic effect of enzalutamide in combination with immunotherapy. This evidence concerns the gene CD274 and prostate carcinoma.